Telix Pharmaceuticals Advances Prostate Cancer Therapy with Phase 3 Trial Expansion

Telix Pharmaceuticals ( (AU:TLX) ) has provided an announcement.

Telix Pharmaceuticals has announced the dosing of the first patient in Part 2 of its ProstACT Global Phase 3 study, which evaluates the prostate cancer therapy candidate TLX591 in patients with metastatic castration-resistant prostate cancer. This trial is notable for combining a PSMA-targeted radio antibody drug conjugate therapy with standard care treatments. The study is expanding globally, with recruitment ongoing in several countries, and plans to submit data to the FDA to further expand the trial in the U.S. This milestone is significant for Telix’s prostate cancer therapeutics pipeline and may enhance its industry positioning by potentially offering a new treatment option with fewer adverse effects compared to existing therapies.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company that specializes in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. The company is headquartered in Melbourne, Australia, and operates internationally in the United States, United Kingdom, Brazil, Canada, Europe, and Japan. Telix focuses on addressing significant unmet medical needs in oncology and rare diseases, with products such as Illuccix®, a PSMA-PET imaging agent, approved in multiple markets.

YTD Price Performance: -39.82%

Average Trading Volume: 2,033,018

Technical Sentiment Signal: Sell

Current Market Cap: A$5.02B

Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.